Interpretation

11/5/2018 Use of vasopressors and inotropes - UpToDate
Official reprint from UpToDate®

www.uptodate.com ©2018 UpToDate, Inc. and/or its affiliates. All Rights Reserved.
Use of vasopressors and inotropes
Author: Scott Manaker, MD, PhD

Section Editor: Polly E Parsons, MD
Deputy Editor: Geraldine Finlay, MD
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Oct 2018. | This topic last updated: Oct 31, 2018.
INTRODUCTION — Vasopressors are a powerful class of drugs that induce vasoconstriction and thereby elevate mean arterial pressure (MAP).
Vasopressors differ from inotropes, which increase cardiac contractility; however, many drugs have both vasopressor and inotropic effects. Although
many vasopressors have been used since the 1940s, few controlled clinical trials have directly compared these agents or documented improved
outcomes due to their use [1]. Thus, the manner in which these agents are commonly used largely reflects expert opinion, animal data, and the use of
surrogate end points, such as tissue oxygenation, as a proxy for decreased morbidity and mortality.
Basic adrenergic receptor physiology and the principles, complications, and controversies surrounding use of vasopressors and inotropes for treatment
of shock are presented here. Issues related to the differential diagnosis of shock and the use of vasopressors in patients with septic shock are
discussed separately. (See "Definition, classification, etiology, and pathophysiology of shock in adults" and "Evaluation and management of suspected
sepsis and septic shock in adults".)
PHYSIOLOGIC MECHANISMS OF VASOCONSTRICTION — The main categories of adrenergic receptors relevant to vasopressor activity are the
alpha-1, beta-1, and beta-2 adrenergic receptors, as well as the dopamine receptors [2,3].
Alpha adrenergic — Activation of alpha-1 adrenergic receptors, located in vascular walls, induces significant vasoconstriction. Alpha-1 adrenergic
receptors are also present in the heart and can increase the duration of contraction without increased chronotropy. However, clinical significance of this
phenomenon is unclear [4].
Beta adrenergic — Beta-1 adrenergic receptors are most common in the heart and mediate increases in inotropy and chronotropy with minimal
vasoconstriction. Stimulation of beta-2 adrenergic receptors in blood vessels induces vasodilation.
Dopamine — Dopamine receptors are present in the renal, splanchnic (mesenteric), coronary, and cerebral vascular beds; stimulation of these
receptors leads to vasodilation. A second subtype of dopamine receptors causes vasoconstriction by inducing norepinephrine release.
Calcium sensitizers — Some agents increase the sensitivity of the myocardial contractile apparatus to calcium, causing an increase in myofilament
tension development and myocardial contractility (eg, pimobendan, levosimendan). These agents have additional pharmacologic properties, such as
https://www.uptodate.com/contents/use-of-vasopressors-and-inotropes/print 1/19
phosphodiesterase inhibition, which may increase inotropy and vasodilation and contribute significantly to their clinical profile, the details of which are
discussed separately.
Angiotensin — Angiotensin receptors (AT1 and AT2) are G-coupled protein receptors with angiotensin II as their ligand. Angiotensin II is a
vasoconstrictor that is part of the renin-aldosterone-angiotensin (RAAS) system. When receptors are stimulated, cytosolic calcium concentration
increases to mediate vasoconstrictive effects as well as aldosterone and vasopressin secretion [5].
PRINCIPLES — Hypotension may result from hypovolemia (eg, exsanguination), pump failure (eg, severe medically refractory heart failure or shock
complicating myocardial infarction), or a pathologic maldistribution of blood flow (eg, septic shock, anaphylaxis). (See "Definition, classification,
etiology, and pathophysiology of shock in adults" and "Inotropic agents in heart failure with reduced ejection fraction".)
Vasopressors are indicated for a decrease of >30 mmHg from baseline systolic blood pressure, or a mean arterial pressure <60 mmHg when either
condition results in end-organ dysfunction due to hypoperfusion. Hypovolemia should be corrected prior to the institution of vasopressor therapy [6].
(See "Treatment of hypovolemia or hypovolemic shock in adults".)
The rational use of vasopressors and inotropes is guided by three fundamental concepts:
● One drug, many receptors – A given drug often has multiple effects because of actions upon more than one receptor. As an example, dobutamine
increases cardiac output by beta-1 adrenergic receptor activation; however, it also acts upon beta-2 adrenergic receptors and thus induces
vasodilation and can cause hypotension.
● Dose-response curve – Many agents have dose-response curves, such that the primary adrenergic receptor subtype activated by the drug is
dose-dependent. As an example, dopamine stimulates beta-1 adrenergic receptors at doses of 2 to 10 mcg/kg per minute, and alpha adrenergic
receptors when doses exceed 10 mcg/kg per minute.
● Direct versus reflex actions – A given agent can affect mean arterial pressure (MAP) both by direct actions on adrenergic receptors and by reflex
actions triggered by the pharmacologic response. Norepinephrine-induced beta-1 adrenergic stimulation alone normally would cause tachycardia.
However, the elevated MAP from norepinephrine's alpha-adrenergic receptor-induced vasoconstriction results in a reflex decrease in heart rate.
The net result may be a stable or slightly reduced heart rate when the drug is used.
PRACTICAL ISSUES — Use of vasopressors and inotropic agents requires attention to a number of issues:
Volume resuscitation — Repletion of adequate intravascular volume, when time permits, is crucial prior to the initiation of vasopressors. As an
example, most patients with septic shock require at least 2 liters of intravenous fluid in order for vasopressors to be maximally effective [7].
Vasopressors will be ineffective or only partially effective in the setting of coexistent hypovolemia.
Fluids may be withheld in patients with significant pulmonary edema due to the acute respiratory distress syndrome (ARDS) or heart failure (HF). In
patients with a pulmonary artery catheter, pulmonary capillary wedge pressures (PCWP) of 18 to 24 mmHg are recommended for cardiogenic shock
[8], and 12 to 14 mmHg for septic or hypovolemic shock [9]. (See "Pulmonary artery catheterization: Interpretation of hemodynamic values and
waveforms in adults".)
Selection and titration — Choice of an initial agent should be based upon the suspected underlying etiology of shock (eg, dobutamine in cases of
cardiac failure without significant hypotension, epinephrine for anaphylactic shock). The dose should be titrated up to achieve effective blood pressure
or end-organ perfusion as evidenced by such criteria as urine output or mentation. If maximal doses of a first agent are inadequate, then a second
drug should be added to the first. In situations where this is ineffective, such as refractory septic shock, anecdotal reports describe adding a third
agent, although no controlled trials have demonstrated the utility of this approach.
Route of administration — Vasopressors and inotropic agents should be administered through an appropriately positioned central venous catheter, if
available. This facilitates more rapid delivery of the agent to the heart for systemic distribution and eliminates the risk of peripheral extravasation.
When a patient does not have a central venous catheter, vasopressors and inotropic agents can be administered through an appropriately positioned
peripheral intravenous catheter temporarily, until a central venous catheter is inserted [10]. (See "Complications of central venous catheters and their
prevention" and "Overview of central venous access".)
Tachyphylaxis — Responsiveness to these drugs can decrease over time due to tachyphylaxis. Doses must be constantly titrated to adjust for this
phenomenon and for changes in the patient's clinical condition [11,12].
Hemodynamic effects — Mean arterial pressure (MAP) is influenced by systemic vascular resistance (SVR) and cardiac output (CO). In situations
such as cardiogenic shock, elevating SVR increases afterload and the work of an already failing heart, thus potentially lowering CO. Some authors
recommend keeping the SVR approximately 700 to 1000 dynes x sec/cm5 to avoid excessive afterload and to minimize complications from profound
vasoconstriction (calculator 1) [13]. However, there is no consensus regarding an ideal target cardiac index (CI). Studies that have attempted to
maintain a supraphysiologic CI of >4 to 4.5 L/minute per m2 have not shown consistent benefit [14,15]. (See "Oxygen delivery and consumption".)
Subcutaneous delivery of medications — Critically ill patients often receive subcutaneously injected medications, such as heparin and insulin. The
bioavailability of these medications can be reduced during treatment with vasopressors due to cutaneous vasoconstriction.
This was demonstrated in a study that monitored plasma factor Xa levels in three groups of hospitalized patients following the initiation of prophylactic
low molecular weight heparin [16]. Patients who required vasopressor support (dopamine >10 mcg/kg per minute, norepinephrine >0.25 mcg/kg per
minute, or phenylephrine >2 mcg/kg per minute) had decreased factor Xa activity compared to both intensive care unit (ICU) patients who did not
require vasopressors and routine postoperative control patients. The clinical significance of the decrease in plasma factor Xa levels was not
determined.
The authors of the study suggested that patients might need higher doses of LMW heparin to attain adequate thrombosis prophylaxis. Another
approach is to change subcutaneous medications to an intravenous form whenever a patient is receiving vasopressor therapy.
Frequent re-evaluation — Critically ill patients may undergo a second hemodynamic insult which necessitates a change in vasopressor or inotrope
management. The dosage of a given agent should not simply be increased because of persistent or worsening hypotension without reconsideration of
the patient's clinical situation and the appropriateness of the current strategy.
ADRENERGIC AGENTS — Adrenergic agents, such as phenylephrine, norepinephrine, dopamine, and dobutamine, are the most commonly used
vasopressor and inotropic drugs in critically ill patients (table 1). These agents manifest different receptor selectivity and clinical effects (table 2).
Norepinephrine — Norepinephrine (Levophed) acts on both alpha-1 and beta-1 adrenergic receptors, thus producing potent vasoconstriction as well
as a modest increase in cardiac output [6]. A reflex bradycardia usually occurs in response to the increased mean arterial pressure (MAP), such that
the mild chronotropic effect is canceled out and the heart rate remains unchanged or even decreases slightly. Norepinephrine is the preferred
vasopressor for the treatment of septic shock. (See 'Choice of agent in septic shock' below and "Evaluation and management of suspected sepsis and
septic shock in adults".)
Phenylephrine — Phenylephrine (Neo-Synephrine) has purely alpha-adrenergic agonist activity and therefore results in vasoconstriction with minimal
cardiac inotropy or chronotropy. MAP is augmented by raising systemic vascular resistance (SVR) [17]. The drug is useful in the setting of hypotension
with an SVR <700 dynes x sec/cm5 (eg, hyperdynamic sepsis, neurologic disorders, anesthesia-induced hypotension). A potential disadvantage of
phenylephrine is that it may decrease stroke volume, so it is reserved for patients in whom norepinephrine is contraindicated due to arrhythmias or
who have failed other therapies.
Although SVR elevation increases cardiac afterload, most studies document that cardiac output (CO) is either maintained or actually increased among
patients without pre-existing cardiac dysfunction [4,18]. The drug is contraindicated if the SVR is >1200 dynes x sec/cm5.
Epinephrine — Epinephrine (Adrenalin) has potent beta-1 adrenergic receptor activity and moderate beta-2 and alpha-1 adrenergic receptor effects.
Clinically, low doses of epinephrine increase CO because of the beta-1 adrenergic receptor inotropic and chronotropic effects, while the alpha
adrenergic receptor-induced vasoconstriction is often offset by the beta-2 adrenergic receptor vasodilation. The result is an increased CO, with
decreased SVR and variable effects on the MAP [3].However, at higher epinephrine doses the alpha-adrenergic receptor effect predominates,
producing increased SVR in addition to an increased CO. Epinephrine is most often used for the treatment of anaphylaxis, as a second line agent
(after norepinephrine) in septic shock, and for management of hypotension following coronary artery bypass grafting.
Other disadvantages of epinephrine include dysrhythmias (due to beta-1 adrenergic receptor stimulation) and splanchnic vasoconstriction. The degree
of splanchnic vasoconstriction appears to be greater with epinephrine than with equipotent doses of norepinephrine or dopamine in patients with
severe shock [19], although the clinical importance of this is unclear.
Ephedrine — Similar to epinephrine, ephedrine acts primarily on alpha- and beta-adrenergic receptors, but with less potency. It also has an effect by
leading to release of endogenous norepinephrine. Ephedrine is rarely used except in the setting of post-anesthesia-induced hypotension.
Dopamine — Dopamine (Intropin) has a variety of effects depending upon the dose range administered. It is most often used as a second-line
alternative to norepinephrine in patients with absolute or relative bradycardia and a low risk of tachyarrhythmias. Weight-based administration of
dopamine can achieve quite different serum drug concentrations in different individuals [20], but the following provides an approximate description of
effects:
● At doses of 1 to 2 mcg/kg per minute, dopamine acts predominantly on dopamine-1 receptors in the renal, mesenteric, cerebral, and coronary
beds, resulting in selective vasodilation. Some reports suggest that dopamine increases urine output by augmenting renal blood flow and
glomerular filtration rate, and natriuresis by inhibiting aldosterone and renal tubular sodium transport [21-23]. These effects may be blunted by
haloperidol and other butyrophenones [23]. However, the clinical significance of these phenomena is unclear, and some patients may develop
hypotension at these low doses [24]. (See "Renal actions of dopamine".)
● At 5 to 10 mcg/kg per minute, dopamine also stimulates beta-1 adrenergic receptors and increases cardiac output, predominantly by increasing
stroke volume with variable effects on heart rate [25]. Doses between 2 and 5 mcg/kg per minute have variable effects on hemodynamics in
individual patients: vasodilation is often balanced by increased stroke volume, producing little net effect upon systemic blood pressure. Some mild
alpha adrenergic receptor activation increases SVR, and the sum of these effects is an increase in MAP.
● At doses >10 mcg/kg per minute, the predominant effect of dopamine is to stimulate alpha-adrenergic receptors and produce vasoconstriction with
an increased SVR [25,26]. However, the overall alpha-adrenergic receptor effect of dopamine is weaker than that of norepinephrine, and the beta-
1 adrenergic receptor stimulation of dopamine at doses >2 mcg/kg per minute can result in dose-limiting dysrhythmias.
In practical terms, the dose-dependent effects of dopamine mean that changing the dose of the drug is akin to switching vasopressors. Conversely,
simply increasing the dose of dopamine without being cognizant of the different receptor populations activated can cause untoward results.
The usual dose range for dopamine is 2 to 20 mcg/kg per minute, although doses as high as 130 mcg/kg per minute have been employed [27]. When
used for cardiac failure, dopamine should be started at 2 mcg/kg per minute and then titrated to a desired physiologic effect rather than depending on
the predicted pharmacologic ranges described above.
Dobutamine — Dobutamine (Dobutrex) is not a vasopressor but rather is an inotrope that causes vasodilation. Dobutamine's predominant beta-1
adrenergic receptor effect increases inotropy and chronotropy and reduces left ventricular filling pressure. In patients with heart failure this results in a
reduction in cardiac sympathetic activity [28]. However, minimal alpha- and beta-2 adrenergic receptor effects result in overall vasodilation,
complemented by reflex vasodilation to the increased CO. The net effect is increased CO, with decreased SVR with or without a small reduction in
blood pressure.
Dobutamine is most frequently used in severe, medically refractory heart failure and cardiogenic shock and should not be routinely used in sepsis
because of the risk of hypotension. Dobutamine does not selectively vasodilate the renal vascular bed, as dopamine does at low doses. (See
"Inotropic agents in heart failure with reduced ejection fraction".)
Isoproterenol — Isoproterenol (Isuprel) also is primarily an inotropic and chronotropic agent rather than a vasopressor. It acts upon beta-1 adrenergic
receptors and, unlike dobutamine, has a prominent chronotropic effect. The drug's high affinity for the beta-2 adrenergic receptor causes vasodilation
and a decrease in MAP. Therefore, its utility in hypotensive patients is limited to situations in which hypotension results from bradycardia.
Contraindications and interactions — Several conditions or medications require avoidance of specific agents:
● In patients with cardiogenic shock, norepinephrine is preferred over dopamine as the first-line vasopressor because a subgroup analysis from a
randomized trial found that patients with cardiogenic shock who received dopamine had a higher mortality than those who received
norepinephrine [29]. In addition, dysrhythmias were more common in the dopamine group.
● Patients with pheochromocytoma are at risk of excessive autonomic stimulation from adrenergic vasopressors.
● Dobutamine is contraindicated in the setting of idiopathic hypertrophic subaortic stenosis.
● Patients receiving monoamine oxidase inhibitors are extremely sensitive to vasopressors and, therefore, require much lower doses.
VASOPRESSIN AND ANALOGS — Vasopressin (antidiuretic hormone) is used in the management of diabetes insipidus and esophageal variceal
bleeding; however, it may also be helpful in the management of vasodilatory shock (table 1). Although its precise role in vasodilatory shock remains to
be defined, it is primarily used as a second-line agent in refractory vasodilatory shock, particularly septic shock or anaphylaxis that is unresponsive to
epinephrine [30-36]. It is also used occasionally to reduce the dose of the first-line agent. Terlipressin, a vasopressin analog, has been assessed in
patients with vasodilatory shock [37-42], but it is not available in the United States.
The effects of vasopressin and terlipressin in vasodilatory shock (mostly septic shock) were evaluated in a systematic review that identified 10 relevant
randomized trials (1134 patients) [43]. A meta-analysis of six of the trials (512 patients) compared vasopressin or terlipressin with placebo or
supportive care. There was no significant improvement in short-term mortality among patients who received either vasopressin or terlipressin (40.2
versus 42.9 percent, relative risk 0.91, 95% CI 0.79-1.05). However, patients who received vasopressin or terlipressin required less norepinephrine. A
second randomized trial compared vasopressin with norepinephrine in 409 patients with septic shock. Although vasopressin did not improve mortality
or the number of kidney failure-free days, it may have been associated with a reduction in the rate of kidney failure requiring renal replacement therapy
(25 versus 35 percent) [44]. Further studies are needed before vasopressin can replace norepinephrine as the first-choice agent for those with septic
shock. (See 'Choice of agent in septic shock' below.)
The effects of vasopressin may be dose dependent. A randomized trial compared two doses of vasopressin (0.0333 versus 0.067 IU/min) in 50
patients with vasodilatory shock who required vasopressin as a second pressor agent [45]. The higher dose was more effective at increasing the blood
pressure without increasing the frequency of adverse effects in these patients. However, doses of vasopressin above 0.03 units/min have been
associated with coronary and mesenteric ischemia and skin necrosis in some studies [46-49], although some of these studies were in animals and
necrosis in humans may also have been due to coexisting conditions (eg, disseminated intravascular coagulation). However, doses higher than the
therapeutic range (0.04 units/min) are generally avoided for this reason unless an adequate mean arterial pressure (MAP) cannot be attained with
other vasopressor agents.
Based upon clinical experience, hypotension appears to be common following withdrawal of vasopressin. To avoid this, the dose can be slowly tapered
by 0.01 units/minute every 30 to 60 minutes [50,51].
Other potential adverse effects of vasopressin include hyponatremia and pulmonary vasoconstriction [46-49,52]. Terlipressin appears to have a similar
side effect profile to vasopressin. In a meta-analysis of four trials (431 patients) that was conducted as part of the systematic review described above,
there was no significant difference in the frequency of adverse events among patients who received either vasopressin or terlipressin (10.6 versus 11.8
percent, relative risk 0.90, 95% CI 0.49-1.67) [43].
NONADRENERGIC AGENTS — A number of agents produce vasoconstriction or inotropy through nonadrenergic mechanisms, including
phosphodiesterase inhibitors and nitric oxide synthase inhibitors, calcium sensitizers, or angiotensin II.
PDE inhibitors — Phosphodiesterase (PDE) inhibitors, such as inamrinone (formerly known as amrinone) and milrinone, are nonadrenergic drugs
with inotropic and vasodilatory actions. In many ways, their effects are similar to those of dobutamine but with a lower incidence of dysrhythmias. PDE
inhibitors most often are used to treat patients with impaired cardiac function and medically refractory heart failure, but their vasodilatory properties
limit their use in hypotensive patients [25]. Inamrinone is no longer available in North America and most/all other countries so the only intravenous
PDE inhibitor used in the US is milrinone. (See "Inotropic agents in heart failure with reduced ejection fraction".)
NOS inhibitors — Nitric oxide overproduction appears to play a major role in vasodilation induced by sepsis (see "Pathophysiology of sepsis").
Studies of nitric oxide synthase (NOS) inhibitors such as N-monomethyl-L-arginine (L-NMMA) in sepsis demonstrate a dose-dependent increase in
systemic vascular resistance (SVR) [53]. However, cardiac index (CI) and heart rate (HR) decrease, even when patients are treated concomitantly with
norepinephrine or epinephrine. The increase in SVR tends to be offset by the drop in CI, such that mean arterial pressure (MAP) is only minimally
augmented. The clinical utility of this class of drugs remains unproven.
Calcium sensitizers — Several agents increase myocardial contractility (eg, pimobendan, levosimendan) but conclusive evidence of improved
outcomes with their use is lacking [54,55].
Angiotensin II — Preliminary trials have reported an adequate vasopressor effect when synthetic angiotensin II is exogenously administered for
vasodilatory shock (eg, septic shock) [56,57]. Best supporting its role as a vasopressor agent is a randomized trial of 344 patients with vasodilatory
shock (80 percent had sepsis and patients had a normal cardiac output) already receiving high dose norepinephrine or similar vasopressor equivalent
[58]. When compared with placebo, angiotensin II resulted in a greater proportion of patients achieving a 10 mmHg or greater increase in the baseline
mean arterial pressure (MAP) or more or an increase in the MAP to 75 mmHg or higher (70 versus 23 percent), at three hours. There was no effect on
mortality or on the sequential organ failure assessment score. Serious adverse events were no different among the groups. Angiotensin II resulted in
less background vasopressor use and higher heart rates but did not result in life-threatening tachyarrhythmias. Further trials will be required to
compare angiotensin II with other vasopressor agents and to examine its effects in populations other than those with vasodilatory shock before it can
be routinely used as a second line agent for the treatment of shock.
COMPLICATIONS — Vasopressors and inotropic agents have the potential to cause a number of significant complications, including hypoperfusion,
dysrhythmias, myocardial ischemia, local effects, and hyperglycemia. In addition, a number of drug interactions exist.
Hypoperfusion — Excessive vasoconstriction in response to hypotension and vasopressors can produce inadequate perfusion of the extremities,
mesenteric organs, or kidneys. Excessive vasoconstriction with inadequate perfusion, usually with an systemic vascular resistance (SVR) >1300
dynes x sec/cm5, commonly occurs in the setting of inadequate cardiac output or inadequate volume resuscitation.
The initial findings are dusky skin changes at the tips of the fingers and/or toes, which may progress to frank necrosis with autoamputation of the digits.
Compromise of the renal vascular bed may produce renal insufficiency and oliguria, while patients with underlying peripheral artery disease may
develop acute limb ischemia.
Inadequate mesenteric perfusion increases the risk of gastritis, shock liver, intestinal ischemia, or translocation of gut flora with resultant bacteremia.
Despite these concerns, maintenance of MAP with vasopressors appears more effective in maintaining renal and mesenteric blood flow than allowing
the MAP to drop, and maintenance of MAP with vasopressors may be life-saving despite evidence of localized hypoperfusion [17,59].
Dysrhythmias — Many vasopressors and inotropes exert powerful chronotropic effects via stimulation of beta-1 adrenergic receptors. This increases
the risk of sinus tachycardia (most common), atrial fibrillation (potentially with increased atrioventricular nodal [A-V] conduction and therefore an
increased ventricular response), re-entrant atrioventricular node tachycardia, or ventricular tachyarrhythmias.
Adequate volume loading may minimize the frequency or severity of dysrhythmias. Despite this, dysrhythmias often limit the dose and necessitate
switching to another agent with less prominent beta-1 effects. The degree to which the agent affects the frequency of dysrhythmias was illustrated by a
randomized trial of 1679 patients with shock [29]. Dysrhythmias were significantly more common among patients who received dopamine than among
those who received norepinephrine (24.1 versus 12.4 percent).
Myocardial ischemia — The chronotropic and inotropic effects of beta-adrenergic receptor stimulation can increase myocardial oxygen consumption.
While there is usually coronary vasodilation in response to vasopressors [60], perfusion may still be inadequate to accommodate the increased
myocardial oxygen demand. Daily electrocardiograms on patients treated with vasopressors or inotropes may screen for occult ischemia, and
excessive tachycardia should be avoided because of impaired diastolic filling of the coronary arteries.
Local effects — Peripheral extravasation of vasopressors into the surrounding connective tissue can lead to excessive local vasoconstriction with
subsequent skin necrosis. To avoid this complication, vasopressors should be administered via a central vein whenever possible. If infiltration occurs,
local treatment with phentolamine (5 to 10 mg in 10 mL of normal saline) injected subcutaneously can minimize local vasoconstriction [61].
Hyperglycemia — Hyperglycemia may occur due to the inhibition of insulin secretion. The magnitude of hyperglycemia generally is minor and is more
pronounced with norepinephrine and epinephrine than dopamine [22]. Monitoring of blood glucose while on vasopressors can prevent complications of
untreated hyperglycemia.
CONTROVERSIES — Several controversies exist regarding the use of vasopressors and inotropic agents in critically ill patients. Most stem from the
relative paucity of large-scale studies comparing similar patient populations treated with different regimens. The development of clear definitions for the
systemic inflammatory response syndrome, sepsis, and septic shock is a step forward toward comparative trials among standardized patient
populations. (See "Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis".)
Choice of agent in septic shock — The optimal agent in patients with septic shock is unknown and practice varies considerably among experts.
However, based upon meta-analyses of small randomized trials and observational studies, a paradigm shift in practice has occurred such that most
experts prefer to avoid dopamine in this population and favor norepinephrine as the first-choice agent the details of which are discussed separately.
(See "Evaluation and management of suspected sepsis and septic shock in adults", section on 'Vasopressors'.)
"Renal dose" dopamine — Dopamine selectively increases renal blood flow when administered to normal volunteers at 1 to 3 mcg/kg per minute
[62,63]. Animal studies also suggest that low-dose dopamine in the setting of vasopressor-dependent sepsis helps preserve renal blood flow [64]. (See
"Renal actions of dopamine" and "Possible prevention and therapy of ischemic acute tubular necrosis".)
However, a beneficial effect of low or "renal dose" dopamine is less proven in human patients with sepsis or other critical illness. Critically ill patients
who do not have evidence of renal insufficiency or decreased urine output will develop a diuresis in response to dopamine at 2 to 3 mcg/kg per minute,
with variable effects on creatinine clearance, but the benefit of this diuresis is questionable [11,24]. The intervention is not entirely benign because
hypotension and tachycardia may ensue. One small study demonstrated that the addition of low dose dopamine to patients receiving other
vasopressors increases splanchnic blood flow but does not alter other indices of mesenteric perfusion, such as gastric intramucosal pH (pHi) [65].
At present, there are no data to support the routine use of low dose dopamine to prevent or treat acute renal failure or mesenteric ischemia. In general,
the most effective means of protecting the kidneys in the setting of septic shock appears to be the maintenance of mean arterial pressure (MAP) >60
mmHg while attempting to avoid excessive vasoconstriction (ie, the systemic vascular resistance [SVR] should not exceed 1300 dynes x sec/cm5)
[7,13,66,67].
Optimal dosage — Although norepinephrine doses of up to 100 mcg/min in adults are typically used in refractory shock and as salvage therapy in
combination with a second vasopressor agent, there is no well-established maximum dose. Several studies have suggested improved tissue perfusion
when higher doses of norepinephrine (up to 350 mcg/min) are used [13,67] but no survival benefit of high-dose norepinephrine has been conclusively
proven.
Supranormal cardiac index — Elevation of the cardiac index with inotropic agents to supranormal values (ie, >4.5 L/minute per m2) potentially
increases oxygen delivery to peripheral tissues. In theory, increased oxygen delivery may prevent tissue hypoxia and improve outcomes, and initial
studies appeared to support this hypothesis [68-70]. However, later larger trials showed that goal-oriented hemodynamic therapy to increase either
cardiac index to >4.5 L/min per m2 or oxygen delivery to >600 to 650 mL/min per m2 with volume expansion or dobutamine resulted in either no
improvement or worsened morbidity or mortality [14,15,71]. Therefore, the routine administration of vasopressors or inotropes to improve cardiac
output or oxygen delivery to supranormal levels is not advocated. (See "Oxygen delivery and consumption".)
The American Thoracic Society (ATS) statement on the detection, correction, and prevention of tissue hypoxia, as well as other ATS guidelines, can be
accessed through the ATS web site at www.thoracic.org/statements.
SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are
provided separately. (See "Society guideline links: Sepsis in children and adults".)
SUMMARY AND RECOMMENDATIONS
● Vasopressors are a powerful class of drugs that induce vasoconstriction and elevate mean arterial pressure (MAP). (See 'Introduction' above.)
● Alpha-1 adrenergic receptors induce vasoconstriction, while beta-1 receptors induce inotropy plus chronotropy, and beta-2 receptors induce
vasodilation. One subtype of dopamine receptor induces norepinephrine release with subsequent vasoconstriction, although many dopamine
receptors induce vasodilation. Some agents increase the sensitivity of the myocardial contractile apparatus to calcium while others cause direct
vasoconstriction via angiotensin II receptor stimulation. (See 'Physiologic mechanisms of vasoconstriction' above.)
● Vasopressors are indicated for a MAP <60 mmHg, or a decrease of systolic blood pressure that exceeds 30 mmHg from baseline, when either
condition results in end-organ dysfunction due to hypoperfusion. (See 'Principles' above.)
● Hypovolemia should be corrected prior to the institution of vasopressor therapy for maximum efficacy. Patients should be re-evaluated frequently
once vasopressor therapy has been initiated. Common issues that arise include tachyphylaxis, which may require dose titration, and additional
hemodynamic insults, which should be recognized and managed. (See 'Practical Issues' above.)
● Choice of an initial agent should be based upon the suspected underlying etiology of shock (eg, dobutamine for cardiogenic shock without
significant hypotension, norepinephrine for septic and cardiogenic shock with hypotension, epinephrine for anaphylactic shock). (See 'Practical
Issues' above and "Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction", section on 'Vasopressors and
inotropes'.)
● Complications of vasopressor therapy include hypoperfusion (particularly affecting the extremities, mesentery or kidneys), dysrhythmias,
myocardial ischemia, peripheral extravasation with skin necrosis, and hyperglycemia. (See 'Complications' above.)
Use of UpToDate is subject to the Subscription and License Agreement.
REFERENCES
1. Müllner M, Urbanek B, Havel C, et al. Vasopressors for shock. Cochrane Database Syst Rev 2004; :CD003709.
2. AHLQUIST RP. A study of the adrenotropic receptors. Am J Physiol 1948; 153:586.
3. ALLWOOD MJ, COBBOLD AF, GINSBURG J. Peripheral vascular effects of noradrenaline, isopropylnoradrenaline and dopamine. Br Med Bull
1963; 19:132.
4. Williamson AP, Seifen E, Lindemann JP, Kennedy RH. WB4101- and CEC-sensitive positive inotropic actions of phenylephrine in rat cardiac
muscle. Am J Physiol 1994; 266:H2462.
5. Catt KJ, Mendelsohn FA, Millan MA, Aguilera G. The role of angiotensin II receptors in vascular regulation. J Cardiovasc Pharmacol 1984; 6
Suppl 4:S575.
6. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine,
Society of Critical Care Medicine. Crit Care Med 1999; 27:639.
7. Moran JL, O'Fathartaigh MS, Peisach AR, et al. Epinephrine as an inotropic agent in septic shock: a dose-profile analysis. Crit Care Med 1993;
21:70.
8. Calvin JE, Driedger AA, Sibbald WJ. Does the pulmonary capillary wedge pressure predict left ventricular preload in critically ill patients? Crit
Care Med 1981; 9:437.
9. Packman MI, Rackow EC. Optimum left heart filling pressure during fluid resuscitation of patients with hypovolemic and septic shock. Crit Care
Med 1983; 11:165.
10. Datar S, Gutierrez E, Schertz A, Vachharajani V. Safety of Phenylephrine Infusion Through Peripheral Intravenous Catheter in the Neurological
Intensive Care Unit. J Intensive Care Med 2018; 33:589.
11. Lherm T, Troché G, Rossignol M, et al. Renal effects of low-dose dopamine in patients with sepsis syndrome or septic shock treated with
catecholamines. Intensive Care Med 1996; 22:213.
12. Unverferth DA, Blanford M, Kates RE, Leier CV. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med 1980; 69:262.
13. Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103:1826.
14. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J
Med 1995; 333:1025.
15. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;
330:1717.
16. Dörffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet
2002; 359:849.
17. Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component of the pharmacologic support of septic shock. Crit Care
Med 1991; 19:1395.
18. Yamazaki T, Shimada Y, Taenaka N, et al. Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis. Crit Care Med 1982;
10:432.
19. De Backer D, Creteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock:
which is best? Crit Care Med 2003; 31:1659.
20. MacGregor DA, Smith TE, Prielipp RC, et al. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 2000; 92:338.
21. Goldberg LI. Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med 1974; 291:707.
22. HORWITZ D, FOX SM 3D, GOLDBERG LI. Effects of Dopamine in man. Circ Res 1962; 10:237.
23. Dasta JF, Kirby MG. Pharmacology and therapeutic use of low-dose dopamine. Pharmacotherapy 1986; 6:304.
24. Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit Care Med 1994;
22:1919.
25. Löllgen H, Drexler H. Use of inotropes in the critical care setting. Crit Care Med 1990; 18:S56.
26. Steel, A, Bihari, D . Choice of catecholamine: does it matter? Curr Opin Crit Care 2000; 6:347.
27. Hannemann L, Reinhart K, Grenzer O, et al. Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in
septic shock. Crit Care Med 1995; 23:1962.
28. Al-Hesayen A, Azevedo ER, Newton GE, Parker JD. The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart
failure. J Am Coll Cardiol 2002; 39:1269.
29. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779.
30. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004; 30:1276.
31. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752.
32. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock.
Crit Care Med 2001; 29:487.
33. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study.
Circulation 2003; 107:2313.
34. Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Two case reports. Int Arch Allergy Immunol 2004;
134:260.
35. Schummer C, Wirsing M, Schummer W. The pivotal role of vasopressin in refractory anaphylactic shock. Anesth Analg 2008; 107:620.
36. McIntyre WF, Um KJ, Alhazzani W, et al. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial
Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis. JAMA 2018; 319:1889.
37. Albanèse J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit
Care Med 2005; 33:1897.
38. Kam PC, Williams S, Yoong FF. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 2004; 59:993.
39. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359:1209.
40. Leone M, Albanèse J, Delmas A, et al. Terlipressin in catecholamine-resistant septic shock patients. Shock 2004; 22:314.
41. Rodríguez-Núñez A, Fernández-Sanmartín M, Martinón-Torres F, et al. Terlipressin for catecholamine-resistant septic shock in children. Intensive
Care Med 2004; 30:477.
42. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic
shock. Intensive Care Med 2004; 30:597.
43. Polito A, Parisini E, Ricci Z, et al. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. Intensive
Care Med 2012; 38:9.
44. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic
Shock: The VANISH Randomized Clinical Trial. JAMA 2016; 316:509.
45. Torgersen C, Dünser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized,
controlled, open-label trial. Intensive Care Med 2010; 36:57.
46. Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004; 32:1327.
47. Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 2002;
30:1899.
48. Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary
hypertension. Crit Care Med 2002; 30:2548.
49. Dünser MW, Mayr AJ, Tür A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant
vasodilatory shock: incidence and risk factors. Crit Care Med 2003; 31:1394.
50. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877.
51. Jeon K, Song JU, Chung CR, et al. Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic
shock: a prospective randomized trial (DOVSS). Crit Care 2018; 22:131.
52. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock:
2016. Crit Care Med 2017; 45:486.
53. Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28:34.
54. Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for Hemodynamic Support after Cardiac Surgery. N Engl J Med 2017.
55. Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl
J Med 2017.
56. Antonucci E, Gleeson PJ, Annoni F, et al. Angiotensin II in Refractory Septic Shock. Shock 2017; 47:560.
57. Chawla LS, Busse L, Brasha-Mitchell E, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit
Care 2014; 18:534.
58. Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 2017; 377:419.
59. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic
sepsis. JAMA 1994; 272:1354.
60. Bohr DF. Adrenergic receptors in coronary arteries. Ann N Y Acad Sci 1967; 139:799.
61. Peters, JI, Utset, OM. Vasopressors in shock management: Choosing and using wisely. J Crit Illness 1989; 4:62.
62. Hollenberg NK, Adams DF, Mendell P, et al. Renal vascular responses to dopamine: haemodynamic and angiographic observations in normal
man. Clin Sci Mol Med 1973; 45:733.
63. D'Orio V, el Allaf D, Juchmès J, Marcelle R. The use of low doses of dopamine in intensive care medicine. Arch Int Physiol Biochim 1984; 92:S11.
64. Schaer GL, Fink MP, Parrillo JE. Norepinephrine alone versus norepinephrine plus low-dose dopamine: enhanced renal blood flow with
combination pressor therapy. Crit Care Med 1985; 13:492.
65. Meier-Hellmann A, Bredle DL, Specht M, et al. The effects of low-dose dopamine on splanchnic blood flow and oxygen uptake in patients with
septic shock. Intensive Care Med 1997; 23:31.
66. Meadows D, Edwards JD, Wilkins RG, Nightingale P. Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 1988;
16:663.
67. Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock
states. Intensive Care Med 1993; 19:151.
68. Shoemaker WC, Kram HB, Appel PL. Therapy of shock based on pathophysiology, monitoring, and outcome prediction. Crit Care Med 1990;
18:S19.
69. Russell JA, Phang PT. The oxygen delivery/consumption controversy. Approaches to management of the critically ill. Am J Respir Crit Care Med
1994; 149:533.
70. Tuchschmidt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992;
102:216.
71. Alía I, Esteban A, Gordo F, et al. A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with
severe sepsis or septic shock. Chest 1999; 115:453.
Topic 1619 Version 32.0
GRAPHICS
Vasopressors and inotropes in treatment of acute hypotensive states and shock: Adult dose and selected
characteristics
Range of
Usual maximum
US trade
Agent Initial dose maintenance doses used Role in therapy and selected characteristics
name
dose range in refractory
shock
Vasopressors (alpha-1 adrenergic)
Norepinephrine Levophed 8 to 12 2 to 4 35 to 100 Initial vasopressor of choice in septic, cardiogenic, and

(noradrenaline) mcg/minute (0.1 mcg/minute mcg/minute (0.5 hypovolemic shock.
to 0.15 (0.025 to 0.05 to 0.75 Wide range of doses utilized clinically.
mcg/kg/minute) mcg/kg/minute) mcg/kg/minute; Must be diluted; eg, a usual concentration is 4 mg in 250
A lower initial up to 3.3 mL of D5W or NS (16 micrograms/mL).
dose of 5 mcg/kg/minute
mcg/minute may has been needed
be used, eg, in rarely)
older adults
Epinephrine Adrenalin 1 mcg/minute 1 to 10 10 to 35 Initial vasopressor of choice in anaphylactic shock.

(adrenaline) (0.014 mcg/minute mcg/minute Typically an add-on agent to norepinephrine in septic shock
mcg/kg/minute) (0.014 to 0.14 (0.14 to 0.5 when an additional agent is required to raise MAP to target
mcg/kg/minute) mcg/kg/minute) and occasionally an alternative first-line agent if
norepinephrine is contraindicated.
Increases heart rate; may induce tachyarrhythmias and
ischemia.
Elevates lactate concentrations during initial administration
(ie, may preclude use of lactate clearance goal); may
decrease mesenteric perfusion.
Must be diluted; eg, a usual concentration is 1 mg in 250
mL D5W (4 micrograms/mL).
Phenylephrine Neo-Synephrine, 100 to 180 20 to 80 80 to 360 Pure alpha-adrenergic vasoconstrictor.

Vazculep mcg/minute until mcg/minute mcg/minute (1.1 Initial vasopressor when tachyarrhythmias preclude use of
stabilized (0.25 to 1.1 to 6 norepinephrine.
(alternatively, mcg/kg/minute) mcg/kg/minute);
Alternative vasopressor for patients with septic shock who:
0.5 to 2 Doses >6 (1) develop tachyarrhythmias on norepinephrine,
mcg/kg/minute) mcg/kg/minute epinephrine, or dopamine, (2) have persistent shock despite
do not increase use of two or more vasopressor/inotropic agents including
efficacy
according to vasopressin (salvage therapy), or (3) high cardiac output

product with persistent hypotension.
information in May decrease stroke volume and cardiac output in patients
the United States with cardiac dysfunction.
May be given as bolus dose of 50 to100 micrograms to
support blood pressure during rapid sequence intubation.
mL D5W or NS (40 micrograms/mL).
Dopamine Inotropin 2 to 5 5 to 20 20 to >50 An alternative to norepinephrine in septic shock in highly

mcg/kg/minute mcg/kg/minute mcg/kg/minute selected patients (eg, with compromised systolic function or
absolute or relative bradycardia and a low risk of
tachyarrhythmias).
More adverse effects (eg, tachycardia, arrhythmias
particularly at doses ≥20 mcg/kg/minute) and less effective
than norepinephrine for reversing hypotension in septic
shock.
Lower doses (eg, 1 to 3 mcg/kg/minute) should not be used
for renal protective effect and can cause hypotension during
weaning.
mL D5W (1.6 mg/mL); use of a commercially available pre-
diluted solution is preferred.
Antidiuretic hormone
Vasopressin Pitressin, 0.03 units per 0.03 to 0.04 0.04 to 0.07 Add-on to norepinephrine to raise blood pressure to target
(arginine- Vasostrict minute units per minute units/minute; MAP or decrease norepinephrine requirement. Not
vasopressin) (alternatively (not titrated) Doses >0.04 recommended as a replacement for a first-line vasopressor.
0.01 to 0.03 units/minute can Pure vasoconstrictor; may decrease stroke volume and
units/minute cause cardiac cardiac output in myocardial dysfunction or precipitate
initially) ischemia and ischemia in coronary artery disease.
should be Must be diluted; eg, a usual concentration is 25 units in 250
reserved for mL D5W or NS (0.1 units/mL).
salvage therapy
Inotrope (beta 1 adrenergic)
Dobutamine Dobutrex 0.5 to 1 2 to 20 20 to 40 Initial agent of choice in cardiogenic shock with low cardiac
mcg/kg/minute mcg/kg/minute mcg/kg/minute; output and maintained blood pressure.
(alternatively, Doses >20 Add-on to norepinephrine for cardiac output augmentation
2.5 mcg/kg/minute in septic shock with myocardial dysfunction (eg, in elevated
mcg/kg/minute are not left ventricular filling pressures and adequate MAP) or
in more severe recommended in ongoing hypoperfusion despite adequate intravascular
cardiac heart failure and volume and use of vasopressor agents.
decompensation) should be
reserved for Increases cardiac contractility and rate; may cause

salvage therapy hypotension and tachyarrhythmias.
Must be diluted; a usual concentration is 250 mg in 500 mL
D5W or NS (0.5 mg/mL); use of a commercially available
pre-diluted solution is preferred.
Inotrope (nonadrenergic, PDE 3 inhibitor)
Milrinone Primacor Optional loading 0.125 to 0.75 Alternative for short-term cardiac output augmentation to
dose: 50 mcg/kg mcg/kg/minute maintain organ perfusion in cardiogenic shock refractory to
over 10 minutes other agents.
(usually not Increases cardiac contractility and modestly increases heart
given) rate at high doses; may cause peripheral vasodilation,
hypotension, and/or ventricular arrhythmia.
Renally cleared; dose adjustment in renal impairment
needed.
mL D5W (200 micrograms/mL); use of a commercially
available pre-diluted solution is preferred.
All doses shown are for intravenous (IV) administration in adult patients. The initial doses shown in this table may differ from those recommended in
immediate post-cardiac arrest management (ie, advanced cardiac life support). For details, refer to the UpToDate topic review of post-cardiac arrest
management in adults, section on hemodynamic considerations.
Vasopressors can cause life-threatening hypotension and hypertension, dysrhythmias, and myocardial ischemia. They should be administered by use of an
infusion pump adjusted by clinicians trained and experienced in dose titration of intravenous vasopressors using continuous noninvasive electronic
monitoring of blood pressure, heart rate, rhythm, and function. Hypovolemia should be corrected prior to the institution of vasopressor therapy. Reduce
infusion rate gradually; avoid sudden discontinuation.
Vasopressors can cause severe local tissue ischemia; central line administration is preferred. When a patient does not have a central venous catheter,
vasopressors can be temporarily administered in a low concentration through an appropriately positioned peripheral venous catheter (ie, in a large vein)
until a central venous catheter is inserted. The examples of concentrations shown in this table are useful for peripheral (short-term) or central line
administration. Closely monitor catheter site throughout infusion to avoid extravasation injury. In event of extravasation, prompt local infiltration of an
antidote (eg, phentolamine) may be useful for limiting tissue ischemia. Stop infusion and refer to extravasation management protocol.
Vasopressor infusions are high-risk medications requiring caution to prevent a medication error and patient harm. To reduce the risk of making a medication
error, we suggest that centers have available protocols that include steps on how to prepare and administer vasopressor infusions using a limited number of
standardized concentrations. Examples of concentrations and other detail are based on recommendations used at experienced centers; protocols can vary by
institution.
D5W: 5% dextrose water; MAP: mean arterial pressure; NS: 0.9% saline.
Prepared with data from:

1. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med
2017; 45:486.
2. Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med 2011; 183:847.
3. Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.
Graphic 99963 Version 8.0
Vasoactive medication receptor activity and clinical effects
Receptor activity
Drug Predominant clinical effects
Alpha-1 Beta-1 Beta-2 Dopaminergic
Phenylephrine +++ 0 0 0 SVR ↑ ↑, CO ↔/↑
Norepinephrine +++ ++ 0 0 SVR ↑ ↑, CO ↔/↑
Epinephrine +++ +++ ++ 0 CO ↑ ↑, SVR ↓ (low dose) SVR/↑ (higher dose)
Dopamine (mcg/kg/min)*
0.5 to 2. 0 + 0 ++ CO
5. to 10. + ++ 0 ++ CO ↑, SVR ↑
10. to 20. ++ ++ 0 ++ SVR ↑ ↑
Dobutamine 0/+ +++ ++ 0 CO ↑, SVR ↓
Isoproterenol 0 +++ +++ 0 CO ↑, SVR ↓
+++: Very strong effect; ++: Moderate effect; +: Weak effect; 0: No effect.
* Doses between 2. and 5. mcg/kg/min have variable effects.
Graphic 63100 Version 1.0
Contributor Disclosures
Scott Manaker, MD, PhD Consultant/Advisory boards: Expert witness in workers' compensation and in medical negligence matters [General
pulmonary and critical care medicine]. Equity Ownership/Stock Options (Spouse): Johnson & Johnson; Pfizer (Numerous medications and devices).
Other Financial Interest: Director of ACCP Enterprises, a wholly owned for-profit subsidiary of ACCP [General pulmonary and critical care medicine
(Providing pulmonary and critical care medicine education to non-members of ACCP)]. Polly E Parsons, MD Nothing to disclose Geraldine Finlay,
MD Nothing to disclose
Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level
review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all
authors and must conform to UpToDate standards of evidence.
Conflict of interest policy

Interpretation

Încărcat de

Informații document

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Interpretation

Încărcat de

Drepturi de autor:

Formate disponibile

11/5/2018 Use of vasopressors and inotropes - UpToDate

Official reprint from UpToDate®

Use of vasopressors and inotropes

Author: Scott Manaker, MD, PhD

● Dobutamine is contraindicated in the setting of idiopathic hypertrophic subaortic stenosis.

increased ventricular response), re-entrant atrioventricular node tachycardia, or ventricular tachyarrhythmias.

SUMMARY AND RECOMMENDATIONS

Use of UpToDate is subject to the Subscription and License Agreement.

Topic 1619 Version 32.0

Vasopressors (alpha-1 adrenergic)

Norepinephrine Levophed 8 to 12 2 to 4 35 to 100 Initial vasopressor of choice in septic, cardiogenic, and

Epinephrine Adrenalin 1 mcg/minute 1 to 10 10 to 35 Initial vasopressor of choice in anaphylactic shock.

Phenylephrine Neo-Synephrine, 100 to 180 20 to 80 80 to 360 Pure alpha-adrenergic vasoconstrictor.

according to vasopressin (salvage therapy), or (3) high cardiac output

Dopamine Inotropin 2 to 5 5 to 20 20 to >50 An alternative to norepinephrine in septic shock in highly

Inotrope (beta 1 adrenergic)

reserved for Increases cardiac contractility and rate; may cause

Inotrope (nonadrenergic, PDE 3 inhibitor)

Prepared with data from:

Graphic 99963 Version 8.0

Vasoactive medication receptor activity and clinical effects

Phenylephrine +++ 0 0 0 SVR ↑ ↑, CO ↔/↑

Norepinephrine +++ ++ 0 0 SVR ↑ ↑, CO ↔/↑

Epinephrine +++ +++ ++ 0 CO ↑ ↑, SVR ↓ (low dose) SVR/↑ (higher dose)

Dobutamine 0/+ +++ ++ 0 CO ↑, SVR ↓

Isoproterenol 0 +++ +++ 0 CO ↑, SVR ↓

Graphic 63100 Version 1.0

Conflict of interest policy

S-ar putea să vă placă și